Several CAR-T cell therapies targeting B-cell maturation antigen (BCMA), which has a highly plasma cell-specific expression pattern, have demonstrated promising efficacy in patients with relapsed/refractory (R/R) MM, including those with extramedullary disease [15–18]. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.